JANX · Janux Therapeutics Inc
United States · RS rating 80 · As of 2026-11-03
| Price | 17.82 USD |
|---|---|
| 1-day change | +2.1% |
| RS rating (overall / 1M / 3M / 12M) | 80 / 78 / 83 / 27 |
| Stage | Topping |
| Composite / Minervini / CANSLIM score | 30 / 45 / 16 |
| Industry group (rank) | Medical-Biomed/Biotech (154) |
| EPS growth Q/Q | -30.8% |
| Sales growth Q/Q | -100.0% |
| Distance from 52-week high | +48.7% |
| Market cap (USD) | $924.0M |